Gilead Sciences CEO Daniel O'Day: We have the most robust pipeline in company history

Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Gilead CEO Daniel O'Day on remdesivir pricing and ensuring access to treatment

Watch CNBC's full interview with Gilead CEO Dan O'Day

Hear more from CEO Daniel O’Day about Gilead Sciences' investment in U.S. innovation.

Gilead CEO Daniel O'Day: Ending the HIV epidemic is our goal